castle trial outcomes
19% of Patients Flare-Free? CASTLE Shakes Chronic Disease Management
49% of treatment-refractory rheumatoid arthritis patients remained flare-free at 12 months after a CD19-CAR-T infusion in the CASTLE phase 1/2 trial. This result suggests a new therapeutic avenue that could alter day-to-day management of chronic autoimmune disease, offering sustained remission where conventional biologics often fail. Medical Disclaimer: This article